Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

How will India’s leading drugmaker handle legal setbacks, volatile market trends, and competition in generics and specialty products?

This decision delays Sun Pharma's planned US launch of the product, which could be deferred for several months if the company ...

JPMorgan reports that Sun Pharma plans to appeal a judgment and may seek a settlement with Incyte to expedite its product ...

Shares of Sun Pharmaceuticals dropped 3.5% after a court in New Jersey issued an injunction delaying the launch of its drug ...

Pharma giant, Sun Pharmaceutical's launch of its specialty drug Leqselvi in the U.S. market is in limbo as the U.S. District Court in New Jersey has issued a preliminary injunction.

In the worst-case scenario, an unfavourable judgment would prevent Sun Pharma from launching Leqselvi until the patent expires, delaying its market entry.

After a US Court blocked the launch of Leqselvi, a drug used to treat severe alopecia areata, shares of Sun Pharma plunged ...

Leqselvi, projected to generate around $200 million in sales over the next three to four years for Sun Pharma, was slated for ...